TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than…
Category: Trending
EW Group Signs with China’s Largest Healthcare, Sinopharm
European Wellness Biomedical Group (EW Group), announced its partnership with HK VJM Ltd (representing Sinopharm Cloud…
Elevation Oncology Announces Pricing of $50 Million Public Offering
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective…
Redwood Pharma presents positive results from a clinical study with RP501 against dry eye
Redwood Pharma AB (publ) announces positive results from the company’s clinical study with RP501, a medical technology…
Fitness & Yoga Campus, Camp Los Angeles, Warms Up for Summer Expansion in West L.A.
Camp Los Angeles – a one-of-a-kind, multi-disciplinary fitness and yoga destination in Santa Monica – is bringing back the summer…
The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights
The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in…
Global Cellulite Treatment Global Market 2023-2030: Increasing Trend of Anti-Cellulite Massage Presents Opportunities
The “Global Cellulite Treatment Market 2023-2030” report has been added to ResearchAndMarkets.com’s offering. This research report predicts that the global…
BioLineRx to Report First Quarter 2023 Results on May 24, 2023
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it…
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today that the China National Medical Products Administration (“NMPA”)…
Candesant Biomedical Receives FDA Clearance of Brella™¹, the First and Only 3-Minute SweatControl Patch™, to Significantly Reduce Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)
Candesant Biomedical (“Candesant”), a private medical device company focused on the development and commercialization of non-invasive treatments…